The company’s approach to drug design and development first considers the medical need through deep knowledge of the science behind the disease, and then seeks to design a novel chemotype to provide the best chance of success.

Headquartered in San Diego, California, BlossomHill Therapeutics is supported by a group of investors, including Cormorant Asset Management, OrbiMed, Vivo Capital and Colt Ventures.